S. Arneric

发表

(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1994, The Journal of pharmacology and experimental therapeutics.

Rapid assessment of ligand actions with nicotinic acetylcholine receptors using calcium dynamics and FLIPR

D. Donnelly-roberts, S. Arneric, T. Kuntzweiler, 1998 .

Regulatory‐accepted drug development tools are needed to accelerate innovative CNS disease treatments

Volker D. Kern, S. Arneric, D. Stephenson, 2018, Biochemical pharmacology.

Role of voltage-gated calcium channels in ascending pain pathways

Gerald W. Zamponi, S. Arneric, R. Lewis, 2009, Brain Research Reviews.

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team

L. Beckett, K. Blennow, L. Shaw, 2016, Journal of Alzheimer's disease : JAD.

An alternative approach to developing dopamine‐receptor agonists with central presynaptic actions following oral administration: A comparison between apomorphine, bromocriptine, and the novel compound RDS‐127 (2‐di‐n‐propylamino‐4,7‐dimethoxyindane)

J. P. Long, S. Arneric, Stephen P. Arnerić, 1983 .

Structure activity relationships of presynaptic dopamine receptor agonists

J. P. Long, S. Arneric, J. Cannon, 1982, Pharmacology Biochemistry and Behavior.

Calcium‐Dependent Release of Tyrosine in Brain Elicited by Stimulation of Neuropeptide Receptors

D. Reis, S. Arneric, M. P. Meeley, 1987, Journal of neurochemistry.

INTRINSIC CHOLINERGIC MECHANISMS REGULATING CEREBRAL BLOOD FLOW 00 AS A TARGET FOR ORGANO PHOSPHATE ACTION ANNUAL REPORT

S. Arneric, Donald, Reis, 2022 .

S. Arneric, D. Caspary, J. Milbrandt, 1994, Hearing Research.

Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors.

D. Donnelly-roberts, Y. Martin, S. Arneric, 1996, Journal of medicinal chemistry.

Evidence that central dopamine receptors modulate sympathetic neuronal activity to the adrenal medulla to alter glucoregulatory mechanisms

J. P. Long, R. Bhatnagar, S. Arneric, 1984, Neuropharmacology.

Accelerating drug development for Alzheimer's disease through the use of data standards

Jon Neville, Klaus Romero, Hugo Vanderstichele, 2017, Alzheimer's & dementia.

New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures

B. Dickerson, W. Marks, B. Boeve, 2019, Alzheimer's & Dementia.

Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.

Thomas J. Raub, E. Wong, R. Hurst, 2006, Journal of medicinal chemistry.

Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (+/-)-epibatidine in rats.

S. Arneric, M. Decker, A. Bannon, 1998, The Journal of pharmacology and experimental therapeutics.

ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain

S. Arneric, M. Decker, A. Bannon, 1998, Brain Research.

Regulatory Science Objectives and Biomarker Qualification Through Public-Private Partnerships Are Critical to Delivering Innovative Treatments for CNS Diseases

S. Arneric, D. Stephenson, 2019, Translational Medicine in CNS Drug Development.

Tailoring chronic pain treatments for the elderly: are we prepared for the challenge?

S. Arneric, J. Laird, A. Chappell, 2014, Drug discovery today.

Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis

Sterling C. Johnson, A. Toga, G. Frisoni, 2017, JAMA neurology.

Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1998, Bioorganic & medicinal chemistry letters.

Neuroimaging of pain: advances and future prospects.

S. Arneric, D. Stephenson, 2008, The journal of pain : official journal of the American Pain Society.

Cloning and transient expression of genes encoding the human α4 and β2 neuronal nicotinic acetylcholine receptor (nAChR) subunits

S. Arneric, J. Sullivan, T. Giordano, 1995 .

Cloning and transient expression of genes encoding the human alpha 4 and beta 2 neuronal nicotinic acetylcholine receptor (nAChR) subunits.

S. Arneric, J. Sullivan, T. Giordano, 1995, Gene.

Novel isoxazoles which interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and anxiolytic activities.

S. Arneric, J. Sullivan, D. Garvey, 1994, Journal of medicinal chemistry.

Is domperidone a selective peripheral dopamine-receptor antagonist in vivo?

J. P. Long, S. Arneric, E. Collins, 1982, Neuropharmacology.

Effect of Cholinergic Enhancers on Basal Forebrain Function Governing Cortical Cerebral Blood Flow

S. Arneric, J. Sullivan, J. L. Raszkiewicz, 1995 .

Thyroid hormone regulation of NGF, NT-3 and BDNF RNA in the adult rat brain.

S. Arneric, T. Giordano, S. Watanabe, 1992, Brain research. Molecular brain research.

Inhibition of Insulin Release from Rat Pancreatic Islets by Drugs that Are Analogues of Dopamine

J. P. Long, S. Arneric, L. J. Fischer, 1984, Diabetes.

Evidence for clonidine presynaptically modulating amino acid release in the rostral ventral medulla: role in hypertension

S. Arneric, F. D. Tingley, 1990, Brain Research.

Microsoft Word-56059911-file00

Haedo, O. McManus, S. Arneric, 2011 .

Cholinergic Approaches to Pain Therapy

S. Arneric, 2003 .

Neuronal nicotinic receptors : pharmacology and therapeutic opportunities

S. Arneric, J. Brioni, 1999 .

THE COALITION AGAINST MAJOR DISEASES: TOWARD U.S. FDA QUALIFICATION OF HIPPOCAMPAL VOLUME AS A BIOMARKER FOR ENRICHMENT IN CLINICAL TRIALS FOR PRE-DEMENTIA STAGES OF ALZHEIMER'S DISEASE

Volker D. Kern, D. Hill, Kaori Ito, 2017, Alzheimer's & Dementia.

Cellular distribution of the mRNA for the α7 subunit of the nicotinic acetylcholine receptor in the human cerebral cortex

T. Giordano, H. Schröder, S. Arneric, 1995 .

ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization.

S. Arneric, M. Decker, N. Lin, 1998, The Journal of pharmacology and experimental therapeutics.

Glutamate in the inferior colliculus plays a critical role in audiogenic seizure initiation

S. Arneric, C. Faingold, A. Riaz, 1992, Epilepsy Research.

Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors.

D. Donnelly-roberts, R. Porsolt, S. Arneric, 1998, Science.

ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.

D. Donnelly-roberts, D. Mckenna, S. Arneric, 1998, The Journal of pharmacology and experimental therapeutics.

Somatostatin and cholecystokinin octapeptide differentially modulate the release of [3H]acetylcholine from caudate nucleus but not cerebral cortex: Role of dopamine receptor activation

D. Reis, S. Arneric, 1986, Brain Research.

A sensitive technique for the detection of the α7 neuronal nicotinic acetylcholine receptor antagonist, methyllycaconitine, in rat plasma and brain

S. Arneric, J. Sullivan, J. Turek, 1995, Journal of Neuroscience Methods.

Human α4β2 Neuronal Nicotinic Acetylcholine Receptor in HEK 293 Cells: A Patch-Clamp Study

D. Bertrand, S. Arneric, J. Sullivan, 1996, The Journal of Neuroscience.

Emerging molecular approaches to pain therapy.

E A Kowaluk, S. Arneric, Michael Williams, 1999, Journal of medicinal chemistry.

Novel 2-(2'-furo[3,2-b]pyridinyl) pyrrolidines : Potent neuronal nicotinic acetylcholine receptor ligands

D. Donnelly-roberts, S. Arneric, T. Kuntzweiler, 1997 .

Preclinical Pharmacology of ABT‐418: A Prototypical Cholinergic Channel Activator for the Potential Treatment of Alzheimer's Disease

A. D. Rodrigues, D. Donnelly-roberts, S. Arneric, 1995 .

Neuronal nicotinic receptors: a perspective on two decades of drug discovery research.

S. Arneric, Michael Williams, Michael Williams, 2007, Biochemical pharmacology.

Nicotinic receptor binding of [3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine in rat brain.

S. Arneric, D. Anderson, David J. Anderson, 1994, European journal of pharmacology.

Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.

D. Donnelly-roberts, S. Arneric, C. Briggs, 1998, Journal of medicinal chemistry.

Agonists and Antagonists of Nicotinic Acetylcholine Receptors

S. Arneric, M. Holladay, 2000 .

Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1998, Bioorganic & medicinal chemistry letters.

The role of neuronal nicotinic acetylcholine receptors in antinociception: Effects of ABT-594

D. Donnelly-roberts, S. Arneric, C. Briggs, 1998, Journal of Physiology-Paris.

Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice.

S. Arneric, M. Decker, N. Lin, 1998, European journal of pharmacology.

Effects of a novel dopamine-receptor agonist RDS-127 (2-N,N-di-n-propylamino-4,7-dimethoxyindane), on hormone levels and sexual behavior in the male rat

John T. Clark, J. P. Long, S. Arneric, 1982, Physiology & Behavior.

Potent anorexic-like effects of RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane) in the rat: A comparison with other dopamine-receptor agonists

J. P. Long, S. Arneric, A. Roetker, 1982, Neuropharmacology.

Role of the Nucleus Raphe Magnus in Antinociception Produced by ABT-594: Immediate Early Gene Responses Possibly Linked to Neuronal Nicotinic Acetylcholine Receptors on Serotonergic Neurons

S. Arneric, M. Decker, A. Bannon, 1998, The Journal of Neuroscience.

A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: In Vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand

D. Donnelly-roberts, D. Mckenna, S. Arneric, 1996, Neuropharmacology.

Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics.

S. Arneric, J. Brioni, M. Decker, 1995, Life sciences.

Structure-activity studies on a novel series of cholinergic channel activators based on a heteroaryl ether framework.

S. Arneric, J. Sullivan, D. Garvey, 1999, Bioorganic & medicinal chemistry letters.

ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys.

W. J. Jackson, S. Arneric, J. Buccafusco, 1997, The Journal of pharmacology and experimental therapeutics.

ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.

D. Donnelly-roberts, D. Mckenna, S. Arneric, 1997, The Journal of pharmacology and experimental therapeutics.

ABT‐089 [3‐(2(S)‐pyrrolidinylmethoxy)‐2‐methyl‐pyridine]: An orally effective cholinergic channel modulator with potential once‐a‐day dosing and cardiovascular safety

S. Arneric, J. Sullivan, N. Lin, 1997 .

Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties.

A. D. Rodrigues, D. Donnelly-roberts, S. Arneric, 1997, Journal of medicinal chemistry.

2-(Aryloxymethyl) azacyclic analogues as novel nicotinic acetylcholine receptor (nAChR) ligands

S. Arneric, J. Sullivan, D. Garvey, 1996 .

Somatostatin and CCK-8 modulate release of striatal amino acids: Role of dopamine receptors

D. Reis, S. Arneric, M. P. Meeley, 1986, Peptides.

The pharmacology of (-)-nicotine and novel cholinergic channel modulators.

S. Arneric, J. Sullivan, J. Brioni, 1997, Advances in pharmacology.

Stable expression and pharmacological properties of the human alpha 7 nicotinic acetylcholine receptor.

D. Bertrand, D. Donnelly-roberts, S. Arneric, 1995, European journal of pharmacology.

Altered metabolism of progesterone by hepatic microsomes from rats following dietary exposure to polybrominated biphenyls.

S. Arneric, W. Braselton, J. Hook, 1980, Toxicology and applied pharmacology.

Nicotine effects on the regulation of amyloid precursor protein splicing, neurotrophin and glucose transporter RNA levels in aged rats

S. Arneric, T. Giordano, L. Monteggia, 1994, International Journal of Developmental Neuroscience.

Anxiolytic-Like Effects of the Corticotropin-Releasing Factor1 (CRF1) Antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] Administered Acutely or Chronically at Doses Occupying Central CRF1 Receptors in Rats

S. Arneric, G. Trainor, R. Taub, 2004, Journal of Pharmacology and Experimental Therapeutics.

Anxiolytic-Like Effects of the Corticotropin-Releasing Factor 1 ( CRF 1 ) Antagonist DMP 904 [ 4-( 3-pentylamino )-2 , 7-dimethyl-8-( 2-methyl-4-methoxyphenyl )-pyrazolo-[ 1 , 5-a ]-pyrimidine ] Administered Acutely or Chronically at Doses Occupying Central CRF 1 Receptors in Rats

S. Arneric, G. Trainor, R. Taub, 2004 .

Anxiolytic-like Effects of the CRF1 Antagonist DMP904 Administered Acutely or Chronically at Doses Occupying Central CRF1 Receptors in Rats

S. Arneric, R. Taub, H. Wong, 2003 .

Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor.

M. Smith, L. Takahashi, S. Arneric, 2001, Brain research. Molecular brain research.

Pharmacological effects of 2-aminotetralins, octahydrobenzo[f]quinolines and clonidine on the isolated guinea pig ileum.

J. P. Long, W. Maixner, S. Arneric, 1981, European journal of pharmacology.

Section Review: Central & Peripheral Nervous Systems: Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease

S. Arneric, J. Sullivan, M. Holladay, 1996 .

Synthesis and structure-activity relationships of 2′-(R) and (S) pyrrolidine-modified analogs of the cholinergic channel activator, ABT-418

S. Arneric, J. Sullivan, N. Lin, 1995 .

Maintenance of local cerebral blood flow after acute neuronal death: Possible role of non-neuronal cells

C. Iadecola, D. Reis, S. Arneric, 1990, Neuroscience.

Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement

W. J. Jackson, S. Arneric, J. Buccafusco, 1995, Psychopharmacology.

The influence of Bay K 8644 treatment on (±)-epibatidine-induced analgesia

S. Arneric, M. Decker, K. Gunther, 1995, Brain Research.

Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1996, The Journal of pharmacology and experimental therapeutics.

Synthesis, release and receptor binding of acetylcholine in the C1 area of the rostral ventrolateral medulla: contributions in regulating arterial pressure

D. Reis, P. Ernsberger, S. Arneric, 1990, Brain Research.

A Novel Positive Allosteric Modulator of the α7 Neuronal Nicotinic Acetylcholine Receptor: In Vitro and In Vivo Characterization

D. Bertrand, R. Hurst, M. Hajós, 2005, The Journal of Neuroscience.

Design of sustained-release matrix systems for a highly water-soluble compound, ABT-089

S. Arneric, Y. Qiu, K. Marsh, 1997 .

Effect of cholinesterase inhibitor and exercise on choline acetyltransferase and acetylcholinesterase activities in rat brain regions

S. Arneric, S. Somani, S. Dube, 1991, Pharmacology Biochemistry and Behavior.

Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.

S. Arneric, G. Trainor, H. Wong, 2009, Journal of medicinal chemistry.

Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer DiseaseA Meta-analysis

A. Toga, G. Frisoni, J. Pa, 2017 .

Rapid and simple analysis of DOPA and 5-HTP using high performance liquid chromatography with electrochemical detection

S. Arneric, D. Goodale, J. Flynn, 1981, Brain Research Bulletin.

Cholinergic channel activators: novel opportunities for the treatment of CNS disorders.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1995, Proceedings of the Western Pharmacology Society.

Imidazo[4,5-c]pyridines as corticotropin releasing factor receptor ligands.

S. Arneric, R. Olson, D. Robertson, 2003, Bioorganic & medicinal chemistry letters.

ABT-418: discriminative stimulus properties and effect on ventral tegmental cell activity

S. Arneric, J. Brioni, M. Decker, 1995, Psychopharmacology.

Central nicotinic receptor agonists ABT-418, ABT-089, and (–)-nicotine reduce distractibility in adult monkeys

W. J. Jackson, S. Arneric, J. Buccafusco, 1998, Psychopharmacology.

Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418

W. J. Jackson, S. Arneric, J. Buccafusco, 1997, Psychopharmacology.

Human alpha4beta2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: A patch-clamp study.

M Gopalakrishnan, D Bertrand, D. Bertrand, 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Cortical cerebral blood flow governed by the basal forebrain: Age-related Impairments

S. Arneric, D. Linville, 1991, Neurobiology of Aging.

Enhanced attention in rhesus monkeys as a common factor for the cognitive effects of drugs with abuse potential

S. Arneric, J. Buccafusco, Mark A. Smith, 2003, Psychopharmacology.

Evidence for Nicotinic Receptors Potentially Modulating Nociceptive Transmission at the Level of the Primary Sensory Neuron: Studies with F11 Cells

D. Donnelly-roberts, S. Arneric, P. Puttfarcken, 1997, Journal of neurochemistry.

A fluorescence-based high-throughput screening assay for the identification of T-type calcium channel blockers.

S. Arneric, F. Belardetti, A. Hendricson, 2009, Assay and drug development technologies.

Functional Characterization of the Novel Neuronal Nicotinic Acetylcholine Receptor Ligand GTS-21 In Vitro and In Vivo

W. J. Jackson, D. Donnelly-roberts, S. Arneric, 1997, Pharmacology Biochemistry and Behavior.

Intrinsic neurons in the amygdaloid field projected to by the medial geniculate body mediate emotional responses conditioned to acoustic stimuli

Joseph E LeDoux, D. Reis, J. Iwata, 1986, Brain Research.

In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1996, Brain Research.

Effects of ABT-418, a novel cholinergic channel ligand, on place learning in septal-lesioned rats.

S. Arneric, J. Brioni, M. Decker, 1994, European journal of pharmacology.

Effects of lobeline, a nicotinic receptor agonist, on learning and memory

S. Arneric, M. Decker, M. Majchrzak, 1993, Pharmacology Biochemistry and Behavior.

Antagonism of CRF2 receptors produces anxiolytic behavior in animal models of anxiety

L. Takahashi, S. Arneric, N. Graciani, 2001, Brain Research.

Characterization of [3H]ABT-418: a novel cholinergic channel ligand.

S. Arneric, D. Anderson, J. L. Raszkiewicz, 1995, The Journal of pharmacology and experimental therapeutics.

Effects of ovariectomy, castration, and chronic lithium chloride treatment on stereotyped behavior in rats

J. P. Long, S. Arneric, M. S. Zeit-Har, 2004, Psychopharmacology.

Up-regulation of human alpha7 nicotinic receptors by chronic treatment with activator and antagonist ligands.

S. Arneric, J. Sullivan, M. Messi, 1998, European journal of pharmacology.

Local cholinergic mechanisms participate in the increase in cortical cerebral blood flow elicited by electrical stimulation of the fastigial nucleus in rat

C. Iadecola, D. Reis, S. Arneric, 1987, Brain Research.

Monthly Updates: Monthly Update Central & Peripheral Nervous Systems: Beyond the tobacco debate: Dissecting out the therapeutic potential of nicotine

S. Arneric, M. Williams, 1996 .

Nitric oxide synthase is critical in mediating basal forebrain regulation of cortical cerebral circulation

S. Arneric, J. L. Raszkiewicz, J. Kerwin, 1992, Journal of neuroscience research.

8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.

Lawrence Fitzgerald, Ge Zhang, Harvey Wong, 2009, Journal of medicinal chemistry.

Action of exogenously administered steroid hormones following perinatal exposure to polybrominated biphenyls.

S. Arneric, J. Hook, K. McCormack, 1979, Journal of toxicology and environmental health.

Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors*

Robert A. Copeland, David W. Robertson, Qian Wang, 2000, The Journal of Biological Chemistry.

Nicotinic receptor agonists facilitate retention of avoidance training: participation of dopaminergic mechanisms.

S. Arneric, J. Brioni, Stephen P. Arneric, 1993, Behavioral and neural biology.

Heptyl‐physostigmine enhances basal forebrain control of cortical cerebral blood flow

E. Giacobini, S. Arneric, D. Linville, 1992, Journal of neuroscience research.

Met-enkephalin selectively increases the spontaneous release of amino acid neurotransmitters from rat striatal slices

D. Reis, S. Arneric, M. P. Meeley, 1986, Neuroscience Letters.

Analgesic Effects of a Substituted N-Triazole Oxindole (TROX-1), a State-Dependent, Voltage-Gated Calcium Channel 2 Blocker

Clare London, Joseph L Duffy, Owen B McManus, 2010, Journal of Pharmacology and Experimental Therapeutics.

A novel slow-inactivation-specific ion channel modulator attenuates neuropathic pain

Gerald W. Zamponi, David Parker, Hassan Pajouhesh, 2011, PAIN®.

Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1995, Alzheimer disease and associated disorders.

Chapter 2 – Novel Molecular Approaches to Analgesia

S. Arneric, E. Kowaluk, 1998 .

Dopamine analog-induced hyperglycemia in rats: involvement of the adrenal medulla and the endocrine pancreas.

J. P. Long, S. Arneric, L. J. Fischer, 1984, The Journal of pharmacology and experimental therapeutics.

W. J. Jackson, S. Arneric, J. Buccafusco, 1998, Cerebral cortex.

Role of local neurons in cerebrocortical vasodilation elicited from cerebellum.

C. Iadecola, D. Reis, S. Arneric, 1987, The American journal of physiology.

Concise informed consent to increase data and biospecimen access may accelerate innovative Alzheimer's disease treatments

A. Hake, S. Arneric, P. Dacks, 2017, Alzheimer's & dementia.

Linopirdine (DuP996) facilitates the retention of avoidance training and improves performance of septal-lesioned rats in the water maze

S. Arneric, J. Brioni, M. Decker, 1993, Pharmacology Biochemistry and Behavior.

Presynaptic Markers of Cholinergic Function in Cortex Following Ibotenic Acid Lesion of the Basal Forebrain

E. Giacobini, S. Arneric, K. Sugaya, 1989 .

2-Amino-4,7-dimethoxyindan derivatives: synthesis and assessment of dopaminergic and cardiovascular actions.

J. P. Long, R. Bhatnagar, S. Arneric, 1982, Journal of medicinal chemistry.

RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.

J. P. Long, S. Arneric, D. Goodale, 1983, The Journal of pharmacology and experimental therapeutics.

2-AMINO-4,7-DIMETHOXYINDAN DERIVATIVES: SYNTHESIS AND ASSESSMENT OF DOPAMINERGIC AND CARDIOVASCULAR ACTIONS

J. P. Long, R. Bhatnagar, S. Arneric, 1982 .

Effects of semirigid methoxamine analogs on vascular smooth muscle: studies of methoxy-2-aminotetralin and 2-aminoindane derivatives.

J. P. Long, S. Arneric, J. Mott, 1982, Archives internationales de pharmacodynamie et de therapie.

Basal forebrain control of cortical cerebral blood flow is independent of local cortical neurons

S. Arneric, D. Linville, S. Williams, 1993, Brain Research.

Gain of function mutation of the α7 nicotinic receptor: distinct pharmacology of the human α7V274T variant

D. Mckenna, S. Arneric, J. Sullivan, 1999 .

Local cholinergic mechanisms mediate the cortical vasodilation elicited by electrical stimulation of the fastigial nucleus.

C. Iadecola, D. Reis, S. Arneric, 1986, Acta physiologica Scandinavica. Supplementum.

Synthesis and structure–activity relationships of 5-substituted pyridine analogues of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543: A potent nicotinic receptor ligand

S. Arneric, T. Kuntzweiler, N. Lin, 2001 .

Opportunities in pain therapy:beyond the opioids and NSAIDs

S. Arneric, E. Kowaluk, M. Williams, 1998 .

NEW NICOTINIC AGONISTS AND CEREBRAL BLOOD FLOW

S. Arneric, 1991 .

Characterization of the Substituted N-Triazole Oxindole TROX-1, a Small-Molecule, State-Dependent Inhibitor of Cav2 Calcium Channels

Rodolfo J. Haedo, David Parker, Clare London, 2012, Molecular Pharmacology.

Current and Future Trends in Drug Discovery and Development Related to Nicotinic Receptors

S. Arneric, E. Sher, 2014 .

Spontaneous release of endogenous aspartate and glutamate from rat striatal slices is increased following destruction of local neurons by ibotenic acid

D. Reis, S. Arneric, M. P. Meeley, 1988, Neurochemical Research.

Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant.

D. Mckenna, S. Arneric, J. Sullivan, 1999, European journal of pharmacology.

Treatments for neuropathic pain differentially affect delayed matching accuracy by macaques: Effects of amitriptyline and gabapentin

A. Vazdarjanova, S. Arneric, J. Buccafusco, 2010, PAIN®.

Expression of the α4 isoform of the nicotinic acetylcholine receptor in the fetal human cerebral cortex

H. Schröder, S. Arneric, A. Maelicke, 2001 .

Local and remote microvascular changes in excitotoxin-induced focal brain lesions

C. Iadecola, D. Reis, S. Arneric, 1989, Brain Research.

Nicotinic agonists modulate basal forebrain control of cortical cerebral blood flow in anesthetized rats.

S. Arneric, J. L. Raszkiewicz, D. Linville, 1993, The Journal of pharmacology and experimental therapeutics.

Anxiolytic-like effects of the novel cholinergic channel activator ABT-418.

S. Arneric, J. Brioni, M. Decker, 1994, The Journal of pharmacology and experimental therapeutics.

A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand.

D. Mckenna, S. Arneric, J. Sullivan, 1996, Neuropharmacology.

Functional modulation of human "ganglionic-like" neuronal nicotinic acetylcholine receptors (nAChRs) by L-type calcium channel antagonists.

S. Arneric, J. Sullivan, D. Donnelly‐Roberts, 1995, Biochemical and biophysical research communications.

Quantitative distribution of muscarinic receptors and choline acetyltransferase in rat medulla: examination of transmitter-receptor mismatch

D. Reis, P. Ernsberger, S. Arneric, 1988, Brain Research.

A novel slow-inactivation-specific ion channel modulator attenuates neuropathic pain

S. Arneric, C. Bladen, F. Belardetti, 2011, PAIN®.

ABT‐089 [2‐methyl‐3‐(2‐(s)‐pyrrolidinylmethoxy) pyridine dihydrochloride]: Discriminative stimulus properties and electrophysiological actions

S. Arneric, J. Brioni, M. Decker, 1997 .

ABT-418: A Novel Cholinergic Channel Activator (ChCA) for the Potential Treatment of Alzheimer’s Disease

A. D. Rodrigues, S. Arneric, J. Sullivan, 1994 .

ABT — 418, a Novel Nicotinic Agonist

A. D. Rodrigues, W. J. Jackson, Y. Martin, 1994 .

Analgesic Effects of a Substituted N-Triazole Oxindole (TROX-1), a State-Dependent, Voltage-Gated Calcium Channel 2 Blocker

O. McManus, S. Arneric, A. Swensen, 2010, Journal of Pharmacology and Experimental Therapeutics.

Effects of chlorisondamine on nicotinic receptor binding in whole brain and nicotine‐induced changes in locomotor activity in rats

S. Arneric, E. Cadman, M. Decker, 1994 .